Welcome reception

Welcome and introductions
Saad Usmani & Faith Davies

Session 1: Defining high-risk multiple myeloma (part I)
Chairs: Faith Davies & Martin Kaiser

• Talk title TBC: TBC
• High-risk multiple myeloma in the immunotherapy era: Francesco Maura
• The detection of PR cells at single cell level identifies high risk disease in myeloma: Paola Neri

Panel discussion

Session 2: Defining high-risk multiple myeloma (part II)
Chairs: TBC & TBC

• Frailty: Are there any biomarkers to identify it?: Ashley Rosko
• Triggering immunogenic cell death to overcome high-risk MM: Kenneth Anderson
• Definition and outcomes of high-risk multiple myeloma in recent clinical trials: Martin Kaiser

Panel discussion

 

Break

 

Session 3: Circulating malignant plasma cell biology
Chairs: Bruno Paiva & Amrita Krishnan

• Talk title TBC: Gareth Morgan
• Genomics of disease progression from MGUS to MMA deeper look at circulating tumor cells: Bruno Paiva
• Elevated circulating tumor cell numbers associate with a highly proliferative and genomically complex phenotype in newly-diagnosed multiple myeloma patients: Juan José Garcés
• Talk title TBC: TBC

Panel discussion

Session 4: Extramedullary disease biology
Chairs: Benjamin Barwick & Maximillian Merz

• Extramedullary disease versus paraskeletal disease – is there a biological difference?: Saurabh Zanwar
• Talk title TBC: Mehmet Samur
• Overcoming spatial sampling bias by liquid biopsy: Johannes Waldschmidt

Panel discussion

Lunch

 

Session 5: MMSET disease subset
Chairs: Mattia D’Agostino & Francesco Maura

• Talk title TBC: TBC
• Prognostic impact of t(4;14), alone and in combination with other genomic risk factors: Kylee Maclachlan
• Pharmacologic and phenotypic targeting of t(4;14) MM: Benjamin Barwick
• Talk title TBC: Constantine Mitsiades

Panel discussion

Session 6: Immuno- and targeted therapies and data in high risk (Part 1)
Chairs: TBC & TBC

• Talk title TBC: Ajai Chari
• Resistance to bispecific antibodies, focus on genomics: Holly Lee
• Resistance to bispecific antibodies, focus on high-risk immune profile: TBC

Panel discussion

Break

Session 7: Immuno- and targeted therapies and data in high risk (Part 2)
Chairs: Ross Firestone & Ajai Chari

• Talk title TBC: Nisha Joseph
• Novel myeloid-derived resistance mechanisms for CAR-T/TCE therapies: Samir Parekh
• Talk title TBC (ADCs): TBC

Panel discussion

Session 8: CAR therapies and data in high risk
Chairs: TBC & Sham Mailankody

• Talk title TBC: Roberto Mina
• CAR T-cell therapy for high-risk multiple myeloma: Addressing a critical unmet need: Doris Hansen
• Allogeneic cell therapy platforms: Karlo Perica

Panel discussion

Day 1 conclusions
Saad Usmani

Welcome to Day 2
Saad Usmani

Session 9: MAF/MAFB disease
Chairs: TBC & Brian Walker

• Exploring the oncogenic MAF protein interactome: Anastasios Karadimitris
• Modeling high risk MM genetic and immune features in mice: José Martínez-Climent
• Detecting all patients with MAF dysregulation using clinical whole genome sequencing: Jonathan Keats
• Novel biomarkers for guiding the use of immunotherapies: Frank Zhan

Panel discussion

Session 10: Designing single-arm studies in high-risk MM
Chairs: Marta Chesi & Martin Kaiser

• Preclinical optimization of TCE in multiple myeloma: Marta Chesi
• Bispecific antibody-based approaches to HRMM: Marc Raab
• Talk title TBC: Sham Mailankody
• Leveraging consistent profiling for single-arm trials with external comparators: Martin Kaiser

Panel discussion

Break

Session 11: Designing randomized studies in high-risk MM
Chairs: TBC & TBC

• How I best identify and evaluate response in EMD: Elena Zamagni
• Talk title TBC: TBC
• Talk title TBC: Francesca Gay
• Optimizing the timing of immunotherapy in randomized trials for high-risk myeloma: Binod Dhakal
• Talk title TBC: TBC

Panel discussion

Meeting conclusions and close
Saad Usmani

Lunch and adjourn